Expansion to Scotland will maximise collaboration with scientific and industrial expertise to further the UK leadership in cell and gene therapies
CGT Catapult laboratories and offices to be constructed at University of Edinburgh Institute for Regeneration and Repair, Edinburgh BioQuarter
The Cell and Gene Therapy Catapult (CGT Catapult) today announces that it will establish offices and laboratories in Edinburgh, Scotland. With this expansion CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption.
CGT Catapult Edinburgh is a collaboration with the University of Edinburgh and will be located at the Institute for Regeneration and Repair in the heart of the Edinburgh BioQuarter. CGT Catapult Edinburgh will help to act as a backbone of translational expertise of the UK, to provide practical advice to enable technology development, good manufacturing practices (GMP) translation and clinical trial acceleration to drive company formation and spin-out for the sector in Scotland and the North of England.
The Centre will be led by Dr Jacqueline Barry, Chief Clinical Officer at CGT Catapult, and will work with the strong academic and pharmaceutical services community in central Scotland to drive advanced therapy medicinal product (ATMP) cluster formation and further build the UK’s prominence in ATMP development and supply.
The UK has become the ‘go-to’ place for cell and gene therapy development in Europe, and boasts a complete cell and gene therapy ecosystem. Today’s announcement reinforces this position by drawing on the specific strengths of Edinburgh and the surrounding region.